Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyH-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancerEph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responsesEpidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptorsErk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous systemErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylationCharacterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampusA hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factorErbB receptors: from oncogenes to targeted cancer therapiesProlonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neuFunctional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Targeting of erbB3 receptor to overcome resistance in cancer treatmentOrchestration of ErbB3 signaling through heterointeractions and homointeractions.Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyPI3K mutations in breast cancer: prognostic and therapeutic implicationsChromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastasesThe ErbB signaling network: receptor heterodimerization in development and cancerTreatment of vestibular schwannoma cells with ErbB inhibitorsDirect estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.Mechanisms of activation of receptor tyrosine kinases: monomers or dimers.Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.Bivalence of EGF-like ligands drives the ErbB signaling networkDifferential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancerThe C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.SOX10 directly modulates ERBB3 transcription via an intronic neural crest enhancer.ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependencyGrb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancerUnderstanding resistance to EGFR inhibitors-impact on future treatment strategiesDifferential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimersL1CAM binds ErbB receptors through Ig-like domains coupling cell adhesion and neuregulin signallingThe oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisTherapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancerModeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological responseFatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
P2860
037de9789cd4877014e2b6828b5ce51829cfa5e32d7a2d4ab50cd487e747e47add14883298ba104b3075568c3ff5f0503e366ebe0de8c54cc889803b4bc8b41095edbc8f88534f6f3ac888bd7803d76362ad89b2ab678993775cb3081eb73ff26307730c77be9d5f480866858ef0bf682b3cb7dbee5224cc81b37705737d1809f0cd02cf82b007a8cbd0a33dbc0a536f274185a206b0f5dcb72d165ff9caba7dc9f4b438791205572e2203b4b04ef0b73f69e8dbd7d12fde088325c9e077deebae13fd80dbd85552e77ab5f4dd4810bcf27c68c2550cb25151f4cfa5
P248
Q21284978-D6165B19-8C17-45B7-BE5B-440E5E36864EQ24313793-71D4567F-22BB-4A3D-B784-97DC83820909Q24316974-BAB1793A-82F3-450A-B015-BD56FFB58987Q24532786-8569C4E2-C080-4250-9446-A3EA9E1EBFB4Q24538180-6AD108B9-2078-4AFB-B5A6-3EC09F5CCAE3Q24601534-9B0B227E-A5D6-4F13-BE2A-9985BD4AD7FDQ24621754-ED7B8A44-DC7F-4CC0-A589-C056D484D8FAQ24645951-3E4CB639-47E9-4162-80D2-69F14C75851DQ24648517-0679FFE9-9F35-4A14-A4C7-7E610BFCFF07Q24683709-DF125E7E-F163-4B0E-BE83-DAFB0C291AFBQ24685875-BAB1D942-4DE6-4A8F-B881-8618654CE231Q24813543-FB586B1E-6B31-42A5-B58B-371894C7B47EQ26864668-0D6D241E-2B93-4000-B6D9-AEF68F988317Q27306737-39131A2C-B1FF-4B1B-99A1-2E3A0F0AE5E0Q27646596-909F223C-8142-4E01-A862-175C1B062C49Q28073335-F6734135-6D7B-4699-9EF5-B20760E8EA37Q28081992-3D86AD01-59AB-451C-B375-81AFEADE69F4Q28345662-5929BA7C-FFBB-43A7-BEAF-9AA16C4B8EB2Q29617919-22E7DF42-F321-4E30-8645-9635AFFB6EF9Q30458767-D5017F24-46D7-4888-9B06-DE21C06A7AEDQ33664216-3439ABA3-0A77-4D52-8C41-07AEFAC6B075Q33739262-6B69416F-163E-4D26-8332-4C9DD8C06655Q33842800-D5E282F6-FA2D-4BCF-A852-C27DC081CA8FQ33883884-C7E27FD0-183D-44A8-8981-E63A50A084ECQ33884776-FE41811E-EA4C-4FA9-8571-8CD9681985A1Q33886341-13A386FB-246C-4593-AE28-CE084E70F272Q33887274-B7636792-E2BC-49BB-B6CF-DB8F276B4965Q33888963-08728B3A-2899-4DCB-883E-A5E677CAA815Q33890758-A541A064-335A-4CC6-A3F3-A76319B516A8Q33891080-9A4B6526-AA20-4FD8-A2D5-D7548746A575Q33932242-3B9A2D31-FB44-4847-9D5B-8ADABD31489EQ33963261-9FB6C642-BB75-4202-B05A-2596A5D0C809Q33967189-D1C09780-429A-4ADF-AFF3-5D76FABE6DF3Q34088424-97363B85-E595-4E47-94F6-0D1C17F5B8F8Q34274718-29655B2B-B02B-4389-9A0B-EAEF0E03A354Q34345014-5DAF19D2-47C0-402D-8225-DB9609904948Q34493341-CBB70292-3038-47A5-89EE-FABD3F6CBAC1Q34570753-E3AD9CF6-5024-415C-A06D-BF0757A5CF42Q34600838-F80E3BAD-6778-4FC2-A60B-B3008A3C1BB3Q34613543-C6273918-BB1C-41BC-82FE-D2CCA41AB0FA
P2860
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Heregulin-dependent regulation ...... y heterodimerization with HER3
@ast
Heregulin-dependent regulation ...... y heterodimerization with HER3
@en
Heregulin-dependent regulation ...... y heterodimerization with HER3
@en-gb
Heregulin-dependent regulation ...... y heterodimerization with HER3
@nl
type
label
Heregulin-dependent regulation ...... y heterodimerization with HER3
@ast
Heregulin-dependent regulation ...... y heterodimerization with HER3
@en
Heregulin-dependent regulation ...... y heterodimerization with HER3
@en-gb
Heregulin-dependent regulation ...... y heterodimerization with HER3
@nl
prefLabel
Heregulin-dependent regulation ...... y heterodimerization with HER3
@ast
Heregulin-dependent regulation ...... y heterodimerization with HER3
@en
Heregulin-dependent regulation ...... y heterodimerization with HER3
@en-gb
Heregulin-dependent regulation ...... y heterodimerization with HER3
@nl
P2093
P2860
P921
P3181
P1433
P1476
Heregulin-dependent regulation ...... y heterodimerization with HER3
@en
P2093
C Wallasch
G Niederfellner
P2860
P304
P3181
P407
P577
1995-09-01T00:00:00Z